

Bremzalerbart Biosimilar - Research Grade

Product Code: ICH5231

More Information

Species Reactivity: Human

Target: BETVIA

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Bremzalerbart Biosimilar - Research Grade

Antibodies against the same target: [Atisnolerbart Biosimilar - Research Grade \(ICH5230\)](#), [Umesolerbart Biosimilar - Research Grade \(ICH5282\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of the anti-allergen antibody bremzalerbart, supplied for research use only. It is built around the same target as the originator drug, the major birch pollen allergen Bet v 1-A (BETVIA), and is expressed as a human IgG4-kappa immunoglobulin. The name follows the current WHO/INN scheme, in which the "-ler-" substem denotes an allergen-directed antibody and the "-bart" suffix a monospecific, full-length engineered immunoglobulin. It is not the clinical drug and is not intended for human or veterinary use. As a bulk, low-endotoxin reagent (research grade less than 1 EU/mg; ultra-low options less than 0.5 EU/mg) available at milligram-to-gram scale, it is well suited to preclinical and in-vitro work where a consistent, high-purity antibody against Bet v 1 is needed: as a positive or isotype-matched control, as

a capture or detection reagent in immunoassays, in allergen-binding and neutralization studies, and in reagent-development pipelines. Its recombinant, animal-component-conscious manufacturing supports lot-to-lot reproducibility for method development and assay standardization. Bet v 1-A (BETVIA) is the major allergen of European white birch (*Betula pendula/verrucosa*) pollen and the principal driver of birch-pollen allergy. It is a small, roughly 17 kDa protein of the pathogenesis-related PR-10 family, adopting the characteristic fold with a large hydrophobic cavity that binds ligands such as flavonoids and other small molecules. In sensitized individuals, Bet v 1 is recognized by allergen-specific IgE bound to mast cells and basophils; allergen cross-linking of surface IgE triggers degranulation and the release of histamine and other mediators, producing seasonal rhinoconjunctivitis and, in some patients, asthma. Bet v 1 also promotes Th2-skewed responses and is a frequent cause of pollen-food (oral allergy) syndrome through cross-reactivity with homologous PR-10 proteins in fruits and nuts. Because it dominates the birch IgE response, Bet v 1 is a central target for diagnostics and allergen-directed immunotherapy.

Other names: Major pollen allergen Bet v 1-A

Specificity: Detects human BETVIA

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks